Recent Updates
Recently added Catalysts
CALC Positive Sentiment

CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

Tuesday, July 8, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CalciMedica Inc. will participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025. CEO Rachel Leheny will engage in a fireside chat, which will be accessible via a live webcast. The company focuses on CRAC channel inhibition therapies for inflammatory and immunologic diseases, with promising clinical results from its lead product candidate, Auxora.
Price reaction · baseline $1.61 (2025-07-07 close) · hit pre-market · clean, no other CALC news in the window
day 0 close
-1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent virtual conference enhances visibility.
  • CEO's involvement in discussions may attract investor interest.
  • CalciMedica's lead product candidate has shown positive clinical results.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~12 mo
Medium dilution risk
Lead asset
CM-4620 Injectable Emulsion or CM-4620-IE
Phase 2 · Acute Pancreatitis

Full Press Release Details

LA JOLLA, Calif.,July 8, 2025/PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced thatRachel Leheny, Ph.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference onMonday, July 14, 2025, at2:00 p.m. ET.
A live webcast of the presentation can be accessed in the "IR Events and Presentations" section of CalciMedica's IR website. A replay of the webcast will be archived on the Company's website for 90 days.

About CalciMedicaCalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed. CalciMedica has announced data for a Phase2btrial (called CARPO –NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and for a Phase 2 trial (called CARDEA –NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE –NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). For more information, please visitwww.calcimedica.com.

Contact InformationArgot Partnersemail protected 600-1902

Frequently Asked Questions

When is CalciMedica participating in the conference?

CalciMedica will participate in the conference on July 14, 2025.

Who will represent CalciMedica at the conference?

CEO Rachel Leheny will represent CalciMedica during the event.

What is the focus of CalciMedica's research?

CalciMedica focuses on developing therapies targeting CRAC channel inhibition.

Where can I access the conference webcast?

The webcast can be accessed on CalciMedica's IR website.

ShareAdd on Google
Tags: CALC Viatris Investor Conferences Healthcare CalciMedica H.C. Wainwright Kidney Conference CRAC channel Auxora
Last updated: Jul 8, 2025

Biotech snapshot

Cash runway
$19M liquidity · $2M/mo burn
~12 mo
Medium dilution risk
Lead asset
CM-4620 Injectable Emulsion or CM-4620-IEPhase 2
Acute Pancreatitis →